{"transactions":[{"id":2939185,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":180554,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ArrowMark Life Science Fund, LP, ArrowMark Fundamental Opportunity Fund L.P., CF Ascent LLC, Iron Horse Investments, LLC, Lookfar Investments, LLC, Meridian Small Cap Growth Fund and THB Iron Rose, LLC Life Science Portfolio (together, the \"ArrowMark Funds\").  ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Funds. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Funds. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":180554},"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939184,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":455326,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ArrowMark Life Science Fund, LP, ArrowMark Fundamental Opportunity Fund L.P., CF Ascent LLC, Iron Horse Investments, LLC, Lookfar Investments, LLC, Meridian Small Cap Growth Fund and THB Iron Rose, LLC Life Science Portfolio (together, the \"ArrowMark Funds\").  ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Funds. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Funds. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":455326},"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939183,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":2864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2864},"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939182,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"purchase","acquired":true,"shares":425000,"price":23,"value":9775000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ArrowMark Life Science Fund, LP, ArrowMark Fundamental Opportunity Fund L.P., CF Ascent LLC, Iron Horse Investments, LLC, Lookfar Investments, LLC, Meridian Small Cap Growth Fund and THB Iron Rose, LLC Life Science Portfolio (together, the \"ArrowMark Funds\").  ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Funds. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Funds. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":1060880,"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939181,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":180554,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ArrowMark Life Science Fund, LP, ArrowMark Fundamental Opportunity Fund L.P., CF Ascent LLC, Iron Horse Investments, LLC, Lookfar Investments, LLC, Meridian Small Cap Growth Fund and THB Iron Rose, LLC Life Science Portfolio (together, the \"ArrowMark Funds\").  ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Funds. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Funds. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":635880,"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939180,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":455326,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ArrowMark Life Science Fund, LP, ArrowMark Fundamental Opportunity Fund L.P., CF Ascent LLC, Iron Horse Investments, LLC, Lookfar Investments, LLC, Meridian Small Cap Growth Fund and THB Iron Rose, LLC Life Science Portfolio (together, the \"ArrowMark Funds\").  ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Funds. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Funds. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":455326,"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":2939179,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T22:39:31.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":2864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately upon the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":2864,"source":{"system":"sec-edgar","filing":"0001567619-20-021287","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761920021287/doc1.xml","form_type":"4"}},{"id":3562433,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-04T21:00:21.000Z","date":"2019-04-03","kind":"purchase","acquired":true,"shares":6487,"price":15.42,"value":100029.54,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price.  These shares were purchased in multiple transactions at prices ranging from $15.28 to $15.50, inclusive.  The reporting person undertakes to provide to Precision BioSciences, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by the ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\"). ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":158003,"source":{"system":"sec-edgar","filing":"0001209191-19-023673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119023673/doc4.xml","form_type":"4"}},{"id":3567828,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":9500,"ownership":{"direct":false,"nature":"By THB Iron Rose, LLC Life Science Portfolio"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by the THB Iron Rose, LLC Life Science Portfolio (the \"THB Fund\"). ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4450},"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567827,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":244572,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by the ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\"). ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":114570},"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567826,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"reported_value":502466,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by the ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\"). ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":36946},"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567825,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":9500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4450},"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567824,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":4450,"ownership":{"direct":false,"nature":"By THB Iron Rose, LLC Life Science Portfolio"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by the THB Iron Rose, LLC Life Science Portfolio (the \"THB Fund\"). ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":4450,"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567823,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":114570,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by the ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\"). ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":151516,"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567822,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":36946,"price":13.6,"value":502465.6,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by the ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\"). ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein."}],"balance_after":36946,"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3567821,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:42.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":4450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."}],"balance_after":4450,"source":{"system":"sec-edgar","filing":"0001209191-19-022659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022659/doc4.xml","form_type":"4"}},{"id":3573874,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":144554,"kind":"person","name":"YAO TONY DUNG LING","position":1,"cik":"0001771680","reported_name":"YAO TONY DUNG LING","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2019-03-29T22:37:24.000Z","date":"2019-03-27","kind":"other","acquired":true,"price":500000,"reported_value":502466,"ownership":{"direct":false,"nature":"By ArrowMark Life Science Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2019, ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 1, 2019, ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 1, 2019, ArrowMark Life Science Fund, LP (the \"ArrowMark Fund\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The 2019 Note is held of record by the ArrowMark Fund. ArrowMark Colorado Holdings LLC (\"ArrowMark Colorado\") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein."}],"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":36946},"source":{"system":"sec-edgar","filing":"0001209191-19-021849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119021849/doc4.xml","form_type":"4"}}]}